Pursuant to section 159(4) of the Companies Act, 2017 (the "Act"), the shareholders of the Company are hereby informed that the following seven (7) candidates have filed with the Company notices of their intention along with requisite documents to offer themselves for election as Directors of the Company, at the Extraordinary General Meeting scheduled to be held on Tuesday, July 09, 2024, at 11.00 a.m., at Ramada Karachi Creek, Zulfiqar Street 1, DHA Phase VIII, Karachi:
NAME
CATEGORY
1
Mr. Tariq Moinuddin Khan
Other
2
Mr. Kamran Nishat
Other
3
Mr. Muhammad Kamran Nasir
Other
4
Mr. Mahmud Yar Hiraj
Other
5
Mr. Muhammad Kamran Mirza
Other
6
Mr. Zafar Iqbal Sobani
Independent
7
Ms. Maleeha Humayun Bangash
Independent
Accordingly, shareholders in line with Section 159 of the Act will elect seven (07) directors as fixed by the Board of Directors, for the next three (03) years commencing from July 09, 2024. No intention received under section 159(3) for Female Director category. However, the requirement for having a female director on the Board as specified in the Companies Act, 2017 and accompanying regulations is being complied with. The number of contestants is equal to the number of seats fixed by the Board and will be elected unopposed at the said forthcoming Extraordinary General Meeting.
Detailed profiles of the above candidates are available at the Company's website accessible at www.agp.com.pk.The independent directors have been chosen considering their experience, competencies, diversity, skills and knowledge in compliance with the requirements of Section 166 of the Act and the regulations issued thereunder.
By Order of the Board
Karachi
Umair Mukhtar
Dated: July 02, 2024
Company Secretary
Attachments
Original Link
Original Document
Permalink
Disclaimer
AGP Ltd. published this content on
02 July 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
02 July 2024 04:02:05 UTC.
AGP Limited is a Pakistan-based pharmaceutical company. The principal activities of the Company include import, marketing, export, dealership, distribution, wholesale, and manufacturing of all kinds of pharmaceutical products. It owns a range of products catering to distinct therapeutic needs of the market. It offers a diverse portfolio of products in internal medicine, gynecology, pediatrics, nutraceutical, neuropsychiatry, cardiometabolic, hepatology, and orthopedic. Its products include Afdol, Nebcin, Exotan, Nergab, Febuxin, Zerifax, Protege, Maxna, Lucast, Urso, Kefzol, Algocin, Poze, Analar, Magnus MR, Novafol, Vita-NEM Plus, Colidrop, Daplazole, Lipomax, and Rigix, among others. Its subsidiary includes OBS AGP (Private) Limited (OBS AGP). OBS AGP is in the business of trading pharmaceutical products.
AGP LIMITED 
